Fig. 3

Statistically significant A375 synergistic cytotoxicity. S = Sanguinarine Alkaloid 1 μM; 2 μM or 3 μM. C = Chelerythrine Alkaloid 1 μM; 2 μM or 3 μM. S/C = Sanguinarine and Chelerythrine Alkaloid Combination; 1 μM/1 μM; 2 μM/2 μM; 3 μM/3 μM. S/C/M = Sanguinarine and Chelerythrine and Minor QBAs Combination; 1 μM Group: Sanguinarine 1 μM; Chelerythrine 1 μM; Minor QBA 1 μM (Sanguilutine 0.33 μM/ Chelilutine 0.33 μM/ Chelirubine 0.33 μM). 2 μM Group: Sanguinarine 2 μM; Chelerythrine 2 μM; Minor QBA (Sanguilutine 0.66 μM/ Chelilutine 0.66 μM/ Chelirubine 0.66 μM). 3 μM Group: Sanguinarine 3 μM; Chelerythrine 3 μM; Minor QBA (Sanguilutine 1 μM/ Chelilutine 1 μM/ Chelirubine 1 μM). S/C/M/P = Sanguinarine and Chelerythrine and Minor QBAs and Protopin Alkaloid Combination. 1 μM Group: Sanguinarine 1 μM; Chelerythrine 1 μM; Minor QBA 1 μM (Sanguilutine 0.33 μM/ Chelilutine 0.33 μM/ Chelirubine 0.33 μM); Protopin 1 μM (Protopine 0.5 μM/ Allocryptopine 0.5 μM). 2 μM Group: Sanguinarine 2 μM; Chelerythrine 2 μM; Minor QBA (Sanguilutine 0.66 μM/ Chelilutine 0.66 μM/ Chelirubine 0.66 μM); Protopin 2 μM (Protopine 1 μM/ Allocryptopine 1 μM). 3 μM Group: Sanguinarine 3 μM; Chelerythrine 3 μM; Minor QBA (Sanguilutine 1 μM/ Chelilutine 1 μM/ Chelirubine 1 μM); Protopin 3 μM (Protopine 1.5 μM/ Allocryptopine 1.5 μM). M = Minor QBA Combination;1 μM Group: Sanguilutine 0.33 μM/ Chelilutine 0.33 μM/ Chelirubine 0.33 μM. 2 μM Group: Sanguilutine 0.66 μM/ Chelilutine 0.66 μM/ Chelirubine 0.66 μM. 3 μM Group: Sanguilutine 1 μM/ Chelilutine 1 μM/ Chelirubine 1 μM. Cell viability percentage compared to controls; Cell viability assessed after 24 hr. compound exposure; Cell viability standard error bars; Significance calculated using Dunnetts p value method